CompletedPhase 1NCT01559961

Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome

Studying Interstitial cystitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Trillium Therapeutics Inc.
Principal Investigator
Penka Petrova, PhD, CPS
Trillium Therapeutics Inc.
Intervention
TTI-1612(drug)
Enrollment
28 target
Eligibility
18-65 years · FEMALE
Timeline
20122013

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01559961 on ClinicalTrials.gov

Other trials for Interstitial cystitis

Additional recruiting or active studies for the same condition.

See all trials for Interstitial cystitis

← Back to all trials